AU2003279536A8 - Use of sns insulator of sea urchin for the gene therapy of erythroid cell diseases - Google Patents

Use of sns insulator of sea urchin for the gene therapy of erythroid cell diseases

Info

Publication number
AU2003279536A8
AU2003279536A8 AU2003279536A AU2003279536A AU2003279536A8 AU 2003279536 A8 AU2003279536 A8 AU 2003279536A8 AU 2003279536 A AU2003279536 A AU 2003279536A AU 2003279536 A AU2003279536 A AU 2003279536A AU 2003279536 A8 AU2003279536 A8 AU 2003279536A8
Authority
AU
Australia
Prior art keywords
sns
insulator
gene therapy
sea urchin
erythroid cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003279536A
Other versions
AU2003279536A1 (en
Inventor
Santa Anna Acuto
Rosalba Di Marzo
Aurelio Maggio
Giovanni Spinelli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2003279536A1 publication Critical patent/AU2003279536A1/en
Publication of AU2003279536A8 publication Critical patent/AU2003279536A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2003279536A 2002-10-09 2003-10-09 Use of sns insulator of sea urchin for the gene therapy of erythroid cell diseases Abandoned AU2003279536A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITRM2002A000511 2002-10-09
IT000511A ITRM20020511A1 (en) 2002-10-09 2002-10-09 USE OF THE SEA URCHIN INSULATOR SNS FOR GENE THERAPY OF DISEASES OF Erythroid Cells.
PCT/IT2003/000611 WO2004032973A2 (en) 2002-10-09 2003-10-09 Use of sns insulator of sea urchin for the gene therapy of erythroid cell diseases

Publications (2)

Publication Number Publication Date
AU2003279536A1 AU2003279536A1 (en) 2004-05-04
AU2003279536A8 true AU2003279536A8 (en) 2004-05-04

Family

ID=11456518

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003279536A Abandoned AU2003279536A1 (en) 2002-10-09 2003-10-09 Use of sns insulator of sea urchin for the gene therapy of erythroid cell diseases

Country Status (3)

Country Link
AU (1) AU2003279536A1 (en)
IT (1) ITRM20020511A1 (en)
WO (1) WO2004032973A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX355648B (en) * 2011-04-08 2018-04-26 Univ Leicester Methods for treating conditions associated with masp-2 dependent complement activation.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1217071B1 (en) * 2000-12-22 2010-04-28 Institut National De La Recherche Agronomique Position-independent and tissue specific expression of a transgene in milk of transgenic animals

Also Published As

Publication number Publication date
WO2004032973A2 (en) 2004-04-22
WO2004032973A3 (en) 2004-09-16
AU2003279536A1 (en) 2004-05-04
ITRM20020511A1 (en) 2004-04-10
ITRM20020511A0 (en) 2002-10-09

Similar Documents

Publication Publication Date Title
HK1152952A1 (en) Combination therapy for cell disorders
PL1620133T3 (en) Gene therapy for neurometabolic disorders
AU2003220519A1 (en) Electrode geometries for efficient neural stimulation
IL181305A0 (en) Combinations for the treatment of diseases involving cell proliferation
IL172346A0 (en) Treatment of t cell mediated diseases by inhibition of fgfr3
AU2003237933A1 (en) Use of compounds having gip activity for the treatment of disorders associated with abnormal loss of cells and/or for the treatment of obesity
EP1599123A4 (en) Surface electrode for electrical stimulation of tissue
EP1590002A4 (en) Small interference rna gene therapy
AU2003226676A1 (en) Methods and compositions for the identification, assessment, and therapy of small cell lung cancer
EP1490074A4 (en) Mixed- cell gene therapy
AU2003209226A1 (en) Adiponectin gene therapy
EP1536834A4 (en) Design of chemokine analogs for the treatment of human diseases
AU2003290059A1 (en) Use of cd137 antagonists for the treatment of tumors
PT1487828E (en) Morpholinyl-urea derivatives for use of the treatment of inflamatory diseases
EP1708757A4 (en) Use of human cord blood-derived pluripotent cells for the treatment of disease
AU2003277910A1 (en) Ocular gene therapy
AU2001232787A1 (en) Airway alkalinization as therapy for airway diseases
GB0327384D0 (en) Gene therapy
AU2003246592A1 (en) Tumour marker and the use thereof for the diagnosis and treatment of tumour diseases
AU2003279536A8 (en) Use of sns insulator of sea urchin for the gene therapy of erythroid cell diseases
AU2003256280A1 (en) Methods of delivering gene therapy agents
AU2003285079A1 (en) Neurostimulation therapy manipulation
AU2002335304A1 (en) The use of berberine as insulin sensitizer
GB0013108D0 (en) Extended duration of airway gene therapy
SI2272868T1 (en) Combination therapy for B cell disorders

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase